Amylyx Pharmaceuticals, Inc. (AMLX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-91.8%

$2.30

vs $28.04 price

Levered DCF

$2.33

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

77.91

Safe zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-7.9×	-0.85×	20.16×	-12.4×	-11.89×	-22.87×	-69.5×
P/B	3.74×	1.56×	2.28×	7.22×	-6.92×	-15.29×	-40.24×
P/S	0×	2.95×	2.6×	110.55×	0×	1,569.76×	715.53×
EV / EBITDA	-6.39×	-0.63×	14.87×	-12.18×	-11.33×	-25.87×	926.58×
Gross margin	0.0%	51.8%	93.3%	86.5%	0.0%	-3683.7%	-734.4%
Operating margin	0.0%	-360.2%	10.2%	-905.7%	0.0%	-6000.8%	-950.5%
Net margin	0.0%	-345.4%	12.9%	-892.4%	0.0%	-6504.6%	-1039.0%
Current ratio	14.27×	6.67×	5.66×	8.2×	6.03×	1.86×	0.71×
Debt / equity	0.02×	0.01×	0.01×	0.02×	0×	-0.02×	-0.59×
Interest coverage	0×	0×	0×	0×	0×	-17.05×	-10.62×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-47.4%	-183.1%	11.4%	-58.2%	58.2%	63.4%	58.4%
Return on invested capital	-49.3%	-188.5%	8.0%	-58.0%	-93.7%	-575.5%	1035.4%
Return on assets	-43.5%	-155.8%	9.5%	-50.7%	-83.3%	-299.8%	-460.1%
Free cash flow yield	-10.8%	-65.1%	1.1%	-7.4%	-7.2%	-3.6%	-1.0%
Earnings yield	-12.7%	-117.1%	5.0%	-8.1%	-8.4%	-4.1%	-1.5%
Enterprise value	$921.7M	$182.2M	$823.7M	$2.4B	$995.4M	$1B	$1B
Net debt / EBITDA	1.53×	0.26×	-3×	0.29×	0.57×	0.29×	10.65×
Cash conversion cycle (days)	-2,447	-24	272	680	0	-54	-67